IBDEI15Y ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20532,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20532,1,4,0)
 ;;=4^AC Embl Thorac Vein NEC
 ;;^UTILITY(U,$J,358.3,20532,1,5,0)
 ;;=5^453.87
 ;;^UTILITY(U,$J,358.3,20532,2)
 ;;=^338258
 ;;^UTILITY(U,$J,358.3,20533,0)
 ;;=453.89^^109^1267^8
 ;;^UTILITY(U,$J,358.3,20533,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20533,1,4,0)
 ;;=4^AC Embolism Veins NEC
 ;;^UTILITY(U,$J,358.3,20533,1,5,0)
 ;;=5^453.89
 ;;^UTILITY(U,$J,358.3,20533,2)
 ;;=^338259
 ;;^UTILITY(U,$J,358.3,20534,0)
 ;;=447.1^^109^1267^79
 ;;^UTILITY(U,$J,358.3,20534,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20534,1,4,0)
 ;;=4^Stricture of Artery
 ;;^UTILITY(U,$J,358.3,20534,1,5,0)
 ;;=5^447.1
 ;;^UTILITY(U,$J,358.3,20534,2)
 ;;=^114763
 ;;^UTILITY(U,$J,358.3,20535,0)
 ;;=355.71^^109^1267^28
 ;;^UTILITY(U,$J,358.3,20535,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20535,1,4,0)
 ;;=4^Causalgia of Lower Limb
 ;;^UTILITY(U,$J,358.3,20535,1,5,0)
 ;;=5^355.71
 ;;^UTILITY(U,$J,358.3,20535,2)
 ;;=^295729
 ;;^UTILITY(U,$J,358.3,20536,0)
 ;;=444.89^^109^1267^16
 ;;^UTILITY(U,$J,358.3,20536,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20536,1,4,0)
 ;;=4^Arterial Embolism NEC
 ;;^UTILITY(U,$J,358.3,20536,1,5,0)
 ;;=5^444.89
 ;;^UTILITY(U,$J,358.3,20536,2)
 ;;=^269793
 ;;^UTILITY(U,$J,358.3,20537,0)
 ;;=447.6^^109^1267^17
 ;;^UTILITY(U,$J,358.3,20537,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20537,1,4,0)
 ;;=4^Arteritis NOS
 ;;^UTILITY(U,$J,358.3,20537,1,5,0)
 ;;=5^447.6
 ;;^UTILITY(U,$J,358.3,20537,2)
 ;;=^10396
 ;;^UTILITY(U,$J,358.3,20538,0)
 ;;=445.81^^109^1267^21
 ;;^UTILITY(U,$J,358.3,20538,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20538,1,4,0)
 ;;=4^Atheroembolism,Kidney
 ;;^UTILITY(U,$J,358.3,20538,1,5,0)
 ;;=5^445.81
 ;;^UTILITY(U,$J,358.3,20538,2)
 ;;=^328516
 ;;^UTILITY(U,$J,358.3,20539,0)
 ;;=445.89^^109^1267^22
 ;;^UTILITY(U,$J,358.3,20539,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20539,1,4,0)
 ;;=4^Atheroembolism,Other Site
 ;;^UTILITY(U,$J,358.3,20539,1,5,0)
 ;;=5^445.89
 ;;^UTILITY(U,$J,358.3,20539,2)
 ;;=^328517
 ;;^UTILITY(U,$J,358.3,20540,0)
 ;;=904.9^^109^1267^25
 ;;^UTILITY(U,$J,358.3,20540,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20540,1,4,0)
 ;;=4^Blood Vessel Injury NOS
 ;;^UTILITY(U,$J,358.3,20540,1,5,0)
 ;;=5^904.9
 ;;^UTILITY(U,$J,358.3,20540,2)
 ;;=^275212
 ;;^UTILITY(U,$J,358.3,20541,0)
 ;;=682.9^^109^1267^29
 ;;^UTILITY(U,$J,358.3,20541,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20541,1,4,0)
 ;;=4^Cellulitis NOS
 ;;^UTILITY(U,$J,358.3,20541,1,5,0)
 ;;=5^682.9
 ;;^UTILITY(U,$J,358.3,20541,2)
 ;;=^21160
 ;;^UTILITY(U,$J,358.3,20542,0)
 ;;=682.0^^109^1267^33
 ;;^UTILITY(U,$J,358.3,20542,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20542,1,4,0)
 ;;=4^Cellulitis of Face
 ;;^UTILITY(U,$J,358.3,20542,1,5,0)
 ;;=5^682.0
 ;;^UTILITY(U,$J,358.3,20542,2)
 ;;=^271888
 ;;^UTILITY(U,$J,358.3,20543,0)
 ;;=682.1^^109^1267^34
 ;;^UTILITY(U,$J,358.3,20543,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20543,1,4,0)
 ;;=4^Cellulitis of Neck
 ;;^UTILITY(U,$J,358.3,20543,1,5,0)
 ;;=5^682.1
 ;;^UTILITY(U,$J,358.3,20543,2)
 ;;=^271889
 ;;^UTILITY(U,$J,358.3,20544,0)
 ;;=682.2^^109^1267^35
 ;;^UTILITY(U,$J,358.3,20544,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20544,1,4,0)
 ;;=4^Cellulitis of Trunk
 ;;^UTILITY(U,$J,358.3,20544,1,5,0)
 ;;=5^682.2
 ;;^UTILITY(U,$J,358.3,20544,2)
 ;;=^271890
 ;;^UTILITY(U,$J,358.3,20545,0)
 ;;=414.8^^109^1267^36
 ;;^UTILITY(U,$J,358.3,20545,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20545,1,4,0)
 ;;=4^Chr Ischemic Hrt Disease NEC
 ;;^UTILITY(U,$J,358.3,20545,1,5,0)
 ;;=5^414.8
 ;;
 ;;$END ROU IBDEI15Y
